Literature DB >> 2283894

Suramin: the discovery of an old anticancer drug.

A Zaniboni1.   

Abstract

Suramin, an antitrypanosomal agent used since the early 1920s for the treatment of onchocerciasis and African sleeping sickness is now under active investigation as an antineoplastic drug characterized by an unusual and interesting mechanism of action and by a peculiar pattern of toxicity. Its capacity to interfere with the autocrine loop which promotes the growth of many human tumors as well as the suggested ability to modify the tumoral environment (chiefly by inhibiting the angiogenesis) holds out great promises for a major step forward in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2283894     DOI: 10.1007/bf02987108

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  16 in total

1.  Growth factor production by human colon carcinoma cell lines.

Authors:  M A Anzano; D Rieman; W Prichett; D F Bowen-Pope; R Greig
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

2.  Circulating glycosaminoglycan anticoagulants associated with suramin treatment.

Authors:  M K Horne; C A Stein; R V LaRocca; C E Myers
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

3.  Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group.

Authors:  B D Cheson; A M Levine; D Mildvan; L D Kaplan; P Wolfe; A Rios; J E Groopman; P Gill; P A Volberding; B J Poiesz
Journal:  JAMA       Date:  1987-09-11       Impact factor: 56.272

4.  Analysis of suramin plasma levels by ion-pair high-performance liquid chromatography under isocratic conditions.

Authors:  R M Ruprecht; J Lorsch; D H Trites
Journal:  J Chromatogr       Date:  1986-06-13

5.  Antiproliferative effects of suramin on lymphoid cells.

Authors:  Z Spigelman; A Dowers; S Kennedy; D DiSorbo; M O'Brien; R Barr; R McCaffrey
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

6.  Lack of response to suramin in patients with AIDS and AIDS-related complex.

Authors:  L D Kaplan; P R Wolfe; P A Volberding; P Feorino; J A Levy; D I Abrams; D Kiprov; R Wong; L Kaufman; M S Gottlieb
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

7.  Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors.

Authors:  J S Garrett; S R Coughlin; H L Niman; P M Tremble; G M Giels; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  Suramin: an anticancer drug with a unique mechanism of action.

Authors:  C A Stein; R V LaRocca; R Thomas; N McAtee; C E Myers
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

9.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.

Authors:  R J Coffey; E B Leof; G D Shipley; H L Moses
Journal:  J Cell Physiol       Date:  1987-07       Impact factor: 6.384

10.  Suramin binds to platelet-derived growth factor and inhibits its biological activity.

Authors:  M Hosang
Journal:  J Cell Biochem       Date:  1985       Impact factor: 4.429

View more
  8 in total

1.  Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Authors:  Bei Cheng; Feng Gao; Erica Maissy; Peisheng Xu
Journal:  Acta Biomater       Date:  2018-12-05       Impact factor: 8.947

Review 2.  A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.

Authors:  Sushmitha S Purushotham; Neeharika M N Reddy; Michelle Ninochka D'Souza; Nilpawan Roy Choudhury; Anusa Ganguly; Niharika Gopalakrishna; Ravi Muddashetty; James P Clement
Journal:  Exp Brain Res       Date:  2022-09-05       Impact factor: 2.064

3.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Authors:  G Strassmann; M Fong; C E Freter; S Windsor; F D'Alessandro; R P Nordan
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 4.  Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  M M Walther; W D Figg; W M Linehan
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Synthesis and antiangiogenic activity of N-alkylated levamisole derivatives.

Authors:  Anders N Hansen; Christine D Bendiksen; Lene Sylvest; Tina Friis; Dan Staerk; Flemming Steen Jørgensen; Christian A Olsen; Gunnar Houen
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

6.  Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells.

Authors:  Wataru Kakuguchi; Takao Nomura; Tetsuya Kitamura; Satoko Otsuguro; Kazuhiro Matsushita; Masahiro Sakaitani; Katsumi Maenaka; Kanchu Tei
Journal:  Cancer Med       Date:  2018-11-18       Impact factor: 4.452

Review 7.  Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Authors:  Giancarlo Ghiselli
Journal:  Medicines (Basel)       Date:  2019-07-29

8.  Phosphatase inhibitors with anti-angiogenic effect in vitro.

Authors:  Lene Sylvest; Christine Dam Bendiksen; Gunnar Houen
Journal:  APMIS       Date:  2010-01       Impact factor: 3.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.